규제 업데이트

Pharmacist groups have held relay rallies for 350 days, urging the government to define licensing duties and tighten drug‑handling rules.

The National Assembly Health and Welfare Committee will hold subcommittee sessions on Oct 15 and 16 to examine health‑related legislation, following a plenary meeting on Oct 11.

The Suwon District Court held that a hospital is considered closed when medical services and prescription issuance cease, affecting goodwill return clauses in pharmacy transfer agreements.

Takeda secured FDA clearance for Orzeyful, the first orexin‑based therapy for type‑1 narcolepsy, and experts see potential expansion into arousal, cognition and fatigue treatments.

The White House disclosed the second round of MFN drug‑price negotiations, now focusing on mid‑size pharmaceutical and biotech firms such as Alcon, Astellas and Teva.

The Korean Pharmacists Association held its 349th day rally, urging the government and parliament to clarify pharmacist and herbal pharmacist license scopes and resolve the issue promptly.

The Health and Welfare Committee’s bill review subcommittee is expected to meet in mid‑month to consider pending pharmacist‑related legislation, including amendments to the pharmacist law.

Onnuri clarified that Mega Onnuri pharmacies operate under an independent pharmacist franchise model, detailing the head office’s role and sub‑lease structure after regional societies raised concerns.

MFDS confirms compensation for patients with Stevens‑Johnson syndrome, anaphylactic shock and Dress syndrome after specific drug use.

South Korea's Ministry of Health and Welfare creates a new office to integrate regional, essential and public healthcare, with its first director pledging collaborative action to close medical gaps.

The Korean Pharmaceutical Association confirmed the official name and detailed organization of an emergency response committee aimed at preventing the expansion of convenience‑store drug sales and telemedicine drug delivery.

Korea's Ministry of Health and Welfare unveils a designation system granting generic price incentives to semi‑innovative pharma companies that meet R&D investment thresholds, excluding violations older than five years.